Novavax (NVAX) Cash from Operations Growth (5y) (2015 - 2026)
Novavax (NVAX) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Novavax | 1.25 Bn | 455.46 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.43% |
| Dec 31, 2025 | 21.03% |
| Sep 30, 2025 | 79.43% |
| Jun 30, 2025 | -25.41% |
| Mar 31, 2025 | -51.67% |
| Dec 31, 2024 | -48.79% |
| Sep 30, 2024 | -35.03% |
| Jun 30, 2024 | 65.65% |
| Mar 31, 2024 | -10.55% |
| Dec 31, 2023 | -31.32% |
| Sep 30, 2023 | -3.42% |
| Jun 30, 2023 | -33.88% |
| Mar 31, 2023 | -37.57% |
| Dec 31, 2022 | -22.11% |
| Sep 30, 2022 | 2.61% |
| Jun 30, 2022 | -68.98% |
| Mar 31, 2022 | -14.74% |
| Sep 30, 2021 | 6.05% |
| Jun 30, 2021 | 34.05% |
| Mar 31, 2021 | 62.97% |